Pensions

PSERS sells $820m PE portfolio as it works to shrink exposure

The portfolio sale included full stakes in assets with vintages of 2013 and older and other partial stakes.

Canadian giant PSP Investments shops $1bn-plus portfolio

LP sales accounted for about $40bn, or 59% of activity in the first half, according to Jefferies’ half-year volume report.

Dawson picks up Dutch pension manager MN’s €1.5bn portfolio sale

MN brought the portfolio of private equity fund stakes to market this year, affiliate title Buyouts reported over the summer.

Performance watch: Portfolio Advisors’ secondaries funds

Details of how the firm’s secondaries funds have performed have been disclosed in documents prepared for a US public pension.

Florida SBA faces setback in efforts to introduce securitisations

The $257bn pension has been seeking alternatives to secondaries sales to avoid taking large discounts in such transactions.

North Carolina eyes GP-led secondaries, opens up to more co-investment

The US pension’s investment committed noted the global secondaries market is a more intriguing opportunity after deal volume hit a record in the first half of this year.

What do LPs really think of continuation funds?

Investors including Alaska Permanent, Caisse des Dépôts, Skandia, New York City Retirement Systems and TRS Texas share their views on how this market can be improved and how they are positioning themselves to take advantage of CVs.

GP-leds account for just 3% of annual distributions to LPs – Ham Lane

Data from the consultant prepared for Teachers’ Retirement System of Louisiana shows the strategy still has room to grow.

ERS Texas sets pacing for FY 2025, precedent for use of continuation funds

The decision comes as part of ERS Texas’ continued commitment to the private equity asset class, bumping its fiscal year 2024 target up $50m from last year’s $600m targeted commitment.

CPP Investments emerges as backer of Cinven single-asset CV

Secondaries Investor reported in March that Goldman Sachs and AlpInvest Partners were investors in the deal involving global life science ingredients distributor Barentz.